Naseem Zojwalla
Overview
Explore the profile of Naseem Zojwalla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stewart A, Dimopoulos M, Masszi T, Spicka I, Oriol A, Hajek R, et al.
J Clin Oncol
. 2016 Sep;
34(32):3921-3930.
PMID: 27601539
Purpose To determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide...
2.
Chen W, Hill H, Christie A, Kim M, Holloman E, Pavia-Jimenez A, et al.
Nature
. 2016 Sep;
539(7627):112-117.
PMID: 27595394
Clear cell renal cell carcinoma (ccRCC) is characterized by inactivation of the von Hippel-Lindau tumour suppressor gene (VHL). Because no other gene is mutated as frequently in ccRCC and VHL...
3.
Stewart A, Rajkumar S, Dimopoulos M, Masszi T, Spicka I, Oriol A, et al.
N Engl J Med
. 2014 Dec;
372(2):142-52.
PMID: 25482145
Background: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1...
4.
Papadopoulos K, Siegel D, Vesole D, Lee P, Rosen S, Zojwalla N, et al.
J Clin Oncol
. 2014 Sep;
33(7):732-9.
PMID: 25225420
Purpose: Carfilzomib is an irreversible inhibitor of the constitutive proteasome and immunoproteasome. This phase I study evaluated the maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of carfilzomib administered as a 30-minute...
5.
Rocha-Lima C, Bayraktar S, Macintyre J, Raez L, Flores A, Ferrell A, et al.
Cancer
. 2012 Feb;
118(17):4262-70.
PMID: 22294459
Background: E7974, a synthetic analog of hemiasterlin, interacts with the tubulin molecule and overcomes resistance to other antitubulin drugs (taxanes and vinca alkaloids). Methods: In a phase 1 study, E7974...
6.
Rowinsky E, Schwartz J, Zojwalla N, Youssoufian H, Fox F, Pultar P, et al.
Curr Drug Targets
. 2011 Jul;
12(14):2016-33.
PMID: 21777192
Insulin-like growth factor type-1 receptor (IGF-1R) plays a central role in cell proliferation and survival and is overexpressed in many tumor types. Notably, IGF-1R-mediated signaling confers resistance to diverse cytotoxic,...
7.
Bodle E, Islam N, Kwon S, Zojwalla N, Ahsan H, Senie R
J Immigr Minor Health
. 2007 Jul;
10(3):239-46.
PMID: 17653863
Cancer screening rates are lower among Asian Americans than the general USA population. While prior studies examined characteristics of Asian American patients as predictors of cancer screening, few investigated their...
8.
Grann V, Troxel A, Zojwalla N, Hershman D, Glied S, Jacobson J
Soc Sci Med
. 2005 Jul;
62(2):337-47.
PMID: 16051406
Where and how one lives is associated with cancer survival. This study was designed to assess geographical region of residence, race/ethnicity, and clinical and socioeconomic factors as predictors of survival...